Journal of Infectious Diseases and Immunity
Subscribe to JIDI
Full Name*
Email Address*

Article Number - C8C2F2648704


Vol.6(4), pp. 26-36 , November 2014
DOI: 10.5897/JIDI2013.0127
ISSN: 2141-2375



Review

Cost effectiveness analyses of influenza A (H1N1) vaccination programs: How accurate were they?



Michael F. Beeler*
  • Michael F. Beeler*
  • Department of Mechanical and Industrial Engineering, University of Toronto, Canada. Operations Research Center, MIT, Cambridge, MA, USA.
  • Google Scholar
Dionne M. Aleman
  • Dionne M. Aleman
  • Department of Mechanical and Industrial Engineering, University of Toronto, Canada.
  • Google Scholar
Michael W. Carter
  • Michael W. Carter
  • Department of Mechanical and Industrial Engineering, University of Toronto, Canada.
  • Google Scholar







 Received: 16 September 2013  Accepted: 05 November 2014  Published: 30 November 2014

Copyright © 2014 Author(s) retain the copyright of this article.
This article is published under the terms of the Creative Commons Attribution License 4.0


Three economic evaluations of pandemic influenza A (H1N1) vaccination campaigns in North America concluded that the mass vaccination campaigns would be, or were, highly cost-effective, if not cost-saving. This paper re-assesses each study's analysis and presents three arguments: 1) prediction of vaccine program cost-effectiveness is unrealistic, if not impossible, unless quality surveillance data is available; 2) even when surveillance data is available, vaccine cost-effectiveness calculations can still vary dramatically and need to undergo wider-ranging sensitivity analysis; 3) H1N1 vaccination campaigns in North America were likely not as cost-effective as previously thought. Several recommendations are then made for improving transparency, accuracy, portability, and sensitivity analysis in pharmacoeconomic studies more generally.

 

Key words: Pandemic, influenza, vaccination, immunization, cost-effectiveness, health economics, pharmaco-economics.

Aleman DM, Wibisono TG, Schwartz B (2011). A non-homogeneous mixing model for predicting pandemic spread. Interfaces Special Issue on Humanitarian Applications: Doing Good with OR. J. Interfaces 41:301-315.
Crossref
 
Amico C (2009). How Much Will the H1N1 flu cost the U.S.? Retrieved February 5, 2012. Available at: http://www.pbs.org/newshour/updates/health-july-dec09-flu-costs_10-08/
 
Arnesen T, Trommald M (2004). Roughly right or precisely wrong? Systemic review of quality-of-life weights elicited with the time trade-off method. J. Health Ser. Res. Policy 9:43-50.
Crossref
 
Blackwell T (2010). Ottawa H1N1 spending too high, ineffective: critics. Retrieved February 5, 2012. Available at: http://www.nationalpost.com/news/story.html?id=2770570
 
Canadian Agency for Drugs and Technology in Health (2006). Guidelines for the economic evaluation of health technologies: Canada [3rd Edition]. Available at: http://www.inahta.org/wp-content/themes/inahta/img/AboutHTA_Guidelines_for_the_Economic_Evaluation_of_Health_Technologies.pdf
 
CBC News (2009). Canada to order 50.4 million H1N1 vaccine doses; $400M contract goes to GlaxoSmithKline factory in Quebec City. Retrieved February 3. Available at: http://www.cbc.ca/news/health/story/2009/08/06/swine-flu-vaccine.html
 
Centers for Disease Control and Prevention (2010b). 2009 H1N1 Vaccine Doses Allocated, Ordered, and Shipped by Project Area. Retrieved February 2012. Available at: http://www.cdc.gov/h1n1flu/vaccination/updates/012810.htm
 
Centers for Disease Control and Prevention (2010a). CDC Estimates of 2009 H1N1 Influenza Cases, Hospitalizations and Deaths in the United States, April 2009 - February 13, 2010. Retrieved February 4, 2012. Available at: http://www.cdc.gov/H1N1flu/pdf/2009\_H1N1\_Estimates\_031210\_final.pdf
 
Claxton K, Paulden M, Gravelle H, Brouwer W, Culyer A (2011). Discounting and decision making in the economic evaluation of health care technologies. Health Econ. 20:2-15.
Crossref
 
Durbin A, Corallo A, Wibisono T, Aleman DM, Schwartz B, Coyte PC (2011). A cost effectiveness analysis of the H1N1 vaccine strategy for Ontario, Canada. J. Infect. Dis. Immunol. 3:40-49.
 
Gojovic M, Sander B, Fisman D, Krahn M, Bauch C (2009). Modelling mitigation strategies for pandemic (H1N1) 2009. CMAJ 181:673-680.
Crossref
 
International Society for Pharmacoeconomics and Outcomes Research. (2014). Pharmacoeconomic Guidelines Around the World: Comparative Table. (ISPOR) Retrieved October 27, 2014. Available at: http://www.ispor.org/PEguidelines/COMP1.asp
 
Khazeni N, Hutton D, Garber AM, Hupert N, Owens DK (2009). Effectiveness and cost-effectiveness of vaccination against pandemic influenza (H1N1) 2009. Ann. Intern. Med. 151:829-840.
Crossref
 
Lee BY, Brown ST, Korch GW, Cooley PC, Zimmerman RK, Wheaton WD, Zimmer SM, Grefenstette JJ, Bailey RR, Assi TM, Burke DS (2010). A computer simulation of vaccine prioritization, allocation, and rationing during the 2009 H1N1 influenza pandemic. Vaccine 28:4875-4879.
Crossref
 
Loper R, Lang D, Hill S (2003). Use of pharmacoeconomics in prescribing research. Part 3: cost-effectiveness analysis: a technique for decision-making at the margin. J. Clin. Pharm. Ther. 28:243-249.
Crossref
 
Prosser LA, Lavelle TA, Fiore AE, Bridges CB, Reed C, Jain S, Dunham KM, Meltzer MI (2011). Cost-Effectiveness of 2009 Pandemic Influenza A(H1N1) Vaccination in the United States. PLoS ONE 6:e22308.
Crossref
 
Public Health Agency of Canada. (2010). Fluwatch April 11 to April 17, 2010 (Week 15). Retrieved February 18, 2012. Available at: http://www.phac-aspc.gc.ca/fluwatch/09-10/w15\_10/index-eng.php
 
Reuters (2010). U.S. scales back H1N1 vaccine, cuts CSL order in half. Retrieved February 18, 2012. Available at: http://www.reuters.com/article/2010/01/11/us-flu-us-csl-idUSTRE60A1G820100111
 
Robberstad B (2005). QALYs vs DALYs vs LYs gained: What are the differences, and what difference do they make for health care priority setting? Norsk Epidemiol. 14:183-191.
 
Salomon S, Murray C (2004). A multi-method approach to measuring health-state valuations. Health Econ. 13:281-290.
Crossref
 
Sander B, Bauch CT, Fisman D, Fowler RA, Kwong JC, Maetzel A, McGeer A, Raboud J, Scales DC, Gojovic MZ, Krahn M (2010). Is a mass immunization program for pandemic (H1N1) good value for money? Evidence from the Canadian experience. Vaccine (28):6210-6220.
Crossref
 
Sander B, Bauch C, Fisman DN, Fowler R, Kwong JC, McGeer A, Zivkovic Gojovic M, Krahn M (2009). Is a mass immunization program for pandemic (H1N1) 2009 good value for money? Early evidence from the Canadian experience. PLoS Curr. 17:1:RRN1137.
 
Severens J, Milne R (2004). Discounting Health Outcomes in Economic Evaluation: The Ongoing Debate. Value Health 7:397-401.
Crossref
 
Smith D, Gravelle H (2001). The practice of discounting in economic evaluations of healthcare interventions. Int. J. Technol. Assess. Health Care 17:236-243.
Crossref
 
Torgerson D, Raftery J (1999). Discounting. BMJ Economics notes 319:914-915.
 
Waldie P, Alphonso C (2009). Cost of vaccinating nation hits $1.5 billion and climbing. Retrieved February 5, 2012. Available at: http://www.theglobeandmail.com/life/health-and-fitness/health/conditions/cost-of-vaccinating-the-nation-hits-15-billion-and-climbing/article1318824/
 
Wilson N, Baker MG (2009). The Emerging Influenza Pandemic: Estimating the Case Fatality Ratio. Eur. Surveill. 14(26). pii: 19255.
 
Yarmand H, Ivy J, Roberts S, Bengtson M, Bengtson N (2010). Cost-effectiveness analysis of vaccination and self-isolation in case of H1N1. In: Johansson B, Jain S, Montoya-Torres J, Hugan J, Yucesan E (Ed.), Proceedings of the 2010 Winter Simulation Conference. pp. 2199-2210.
Crossref

 


APA Beeler*, M. F., Aleman, D. M., & Carter, M. W. (2014). Cost effectiveness analyses of influenza A (H1N1) vaccination programs: How accurate were they?. Journal of Infectious Diseases and Immunity, 6(4), 26-36.
Chicago Michael F. Beeler, Dionne M. Aleman and Michael W. Carter  . "Cost effectiveness analyses of influenza A (H1N1) vaccination programs: How accurate were they?." Journal of Infectious Diseases and Immunity 6, no. 4 (2014): 26-36.
MLA Michael F. Beeler, Dionne M. Aleman and Michael W. Carter  . "Cost effectiveness analyses of influenza A (H1N1) vaccination programs: How accurate were they?." Journal of Infectious Diseases and Immunity 6.4 (2014): 26-36.
   
DOI 10.5897/JIDI2013.0127
URL http://academicjournals.org/journal/JIDI/article-abstract/C8C2F2648704

Subscription Form